Pfizer’s vaccine appears to neutralize the Covid variants found in the U.K. and South Africa. The study was conducted by Pfizer and has not been peer reviewed. It comes as countries scramble to deal with more contagious variants of the Covid virus. For access to live and exclusive video from CNBC subscribe to CNBC PRO:
A coronavirus vaccine developed by Pfizer and BioNTech appears to be effective against a key mutation in the more infectious variants of the virus discovered in the U.K. and South Africa, according to a study conducted by the U.S. pharmaceutical giant.
It comes as countries scramble to contain the variants that are significantly more transmissible, with public health experts anxious about the potential impact on inoculation efforts.
The research, published Thursday on preprint server bioRxiv and not yet peer-reviewed, suggested the Pfizer-BioNTech vaccine worked to neutralize the so-called N501Y mutation.
The N501Y mutation has been reported in the more infectious variants. It is altering an amino acid within six key residues in the receptor-binding domain — a key part of the spike protein that the virus uses to gain entry into cells within the body.
“These findings are good news for the likely effectiveness of the Pfizer/BioNTech vaccine against these new variants of SARS-CoV-2,” said Dr. Michael Baker, an epidemiologist at the University of Otago in Wellington, New Zealand.
“In other words, the Pfizer vaccine is likely to induce immunity that covers the two new more infectious variants originating in England and South Africa,” he added.
Pfizer and researchers at the University of Texas Medical Branch conducted the study on blood taken from people who had been given the Covid-19 vaccine.
The findings are limited, however, because the study does not look at the full set of mutations found in either of the new rapidly spreading variants.
“Pfizer and BioNTech have tested sera from people immunized with the BNT162b2 vaccine for its ability to neutralize multiple mutant strains,” a Pfizer spokesperson told CNBC via email on Friday, referring to the official name of the Covid vaccine.
“To date, we have found consistent coverage of all the strains tested. The two companies are now generating data on how well sera from people immunized with BNT162b2, may be able to neutralize new strains.”
‘We urgently need data’
Researchers hope to have more data on whether the vaccines work against other mutations found in the U.K. and South Africa variants in the coming weeks, Reuters reported.
“It’s important to note that the study does not actually examine these variants directly but only focuses on one single mutation in these variants (the 501Y mutation),” Dr. Deepti Gurdasani, clinical epidemiologist at Queen Mary University of London, told CNBC via email on Friday.
“So, while it’s reassuring that one mutation within these variants is not associated with escape from vaccines, at least in the laboratory, we urgently need data on these mutations, and preferably on the variant virus with a combination of mutations, as these may act differently in combination.”
» Subscribe to CNBC TV:
» Subscribe to CNBC:
» Subscribe to CNBC Classic:
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:
Connect with CNBC News Online
Get the latest news:
Follow CNBC on LinkedIn:
Follow CNBC News on Facebook:
Follow CNBC News on Twitter:
Follow CNBC News on Instagram:
#CNBC
#CNBCTV
